(PharmaNewsWire.Com, May 13, 2017 ) Publisher's, "Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher's Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Report Scope - The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors - The report provides the marketed drugs information including its sales, development activities and details of patent expiry - The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling - The report also gives the information of dormant pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage - Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine. - Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics - Developing strategic initiatives to support your drug development activities. - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business. - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents Introduction Executive Summary Executive Summary Snapshot Janus kinase Inhibitors (JAK Inhibitors) Overview Introduction Structure and Mechanism Janus Kinase Inhibitors Types of JAK Inhibitors Cytokines associated with Janus kinases and result of their mutations JAK Inhibitors Market Analysis Collaborations and Deals Acquisition Deals Designations Analysis Grants Financing Companies Involved in JAK Inhibitor Development Therapeutic Targets by Company and Indication Market Drivers and Barriers Drivers Barriers Marketed Products Therapeutics under Development by Companies Late Stage Products (Filed &Phase III) Comparative Analysis Mid Stage Products (Phase II) Comparative Analysis Early Stage Products (Phase Iand IND) Comparative Analysis Discovery and Pre-clinical stage Products Comparative Analysis Therapeutic Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant Products Companies involved in Therapeutics Development Upcoming Conferences SWOT Analysis for JAK Inhibitors
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
